Literature DB >> 21052972

[Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate].

B J Steinhoff1, E Trinka, A S Wendling.   

Abstract

BACKGROUND: Eslicarbazepine acetate (ESL) was labelled for add-on treatment of adults with focal epilepsies in 2009. ESL is a derivative of carbamazepine and oxcarbazepine (OXC) that promises potentially better effectiveness. It has not yet been investigated how to switch from OXC to ESL and if this switch causes any clinical changes.
MATERIAL AND METHODS: We replaced extended-release OXC by ESL abruptly according to a 1:1 ratio in 12 patients. Standardized tests and questionnaires addressing side effects, quality of life and alertness were performed immediately prior and 5 days after the switch. We also measured the serum levels of sodium and the common metabolite monohydroxy derivative.
RESULTS: No problems occurred. Concerning the parameters investigated no significant differences were found. In 9 of 12 cases serum sodium levels fell without clinical consequences.
CONCLUSION: The exchange of extended-release OXC by ESL is easy to perform. Clinically relevant alterations were not apparent immediately after the switch. Sodium serum level controls are recommended also with the use of ESL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21052972     DOI: 10.1007/s00115-010-3177-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  17 in total

1.  Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects.

Authors:  Luis Almeida; Amílcar Falcão; Joana Maia; Dago Mazur; Manfred Gellert; Patrício Soares-da-Silva
Journal:  J Clin Pharmacol       Date:  2005-09       Impact factor: 3.126

2.  Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine.

Authors:  D Hainzl; A Parada; P Soares-da-Silva
Journal:  Epilepsy Res       Date:  2001-05       Impact factor: 3.045

Review 3.  Eslicarbazepine acetate (BIA 2-093).

Authors:  Luis Almeida; Patrício Soares-da-Silva
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

4.  Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.

Authors:  J Benes; A Parada; A A Figueiredo; P C Alves; A P Freitas; D A Learmonth; R A Cunha; J Garrett; P Soares-da-Silva
Journal:  J Med Chem       Date:  1999-07-15       Impact factor: 7.446

5.  Synthesis, anticonvulsant properties and pharmacokinetic profile of novel 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine-5-carboxamide derivatives.

Authors:  D A Learmonth; J Benes; A Parada; D Hainzl; A Beliaev; M J Bonifácio; P M Matias; M A Carrondo; J Garrett; P Soares-da-Silva
Journal:  Eur J Med Chem       Date:  2001-03       Impact factor: 6.514

6.  The metabolism of 14C-oxcarbazepine in man.

Authors:  H Schütz; K F Feldmann; J W Faigle; H P Kriemler; T Winkler
Journal:  Xenobiotica       Date:  1986-08       Impact factor: 1.908

7.  A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10.

Authors:  J A Cramer; K Perrine; O Devinsky; K Meador
Journal:  Epilepsia       Date:  1996-06       Impact factor: 5.864

8.  Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.

Authors:  A Gil-Nagel; J Lopes-Lima; L Almeida; J Maia; P Soares-da-Silva
Journal:  Acta Neurol Scand       Date:  2009-11       Impact factor: 3.209

9.  Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial.

Authors:  F G Gilliam; A J Fessler; G Baker; V Vahle; J Carter; H Attarian
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910

10.  Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.

Authors:  Christian Elger; Peter Halász; Joana Maia; Luis Almeida; Patrício Soares-da-Silva
Journal:  Epilepsia       Date:  2009-02-21       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.